Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-23T07:06:09.755Z Has data issue: false hasContentIssue false

22 - Medication-Induced Psychosis

from Part VI - Substance Abuse and Medications

Published online by Cambridge University Press:  06 January 2010

Junji Takeshita
Affiliation:
University of Hawaii
Diane Thompson
Affiliation:
Queen's Medical Center
Stephen E. Nicolson
Affiliation:
Massachusetts General Hospital
Daryl Fujii
Affiliation:
University of Hawaii, Manoa
Iqbal Ahmed
Affiliation:
University of Hawaii, Manoa
Get access

Summary

Medication-induced psychosis is a common occurrence. Both in and out of the hospital, patients with multiple health problems are at an increased risk of developing both psychosis and delirium with the addition of prescription and over-the-counter medications. This chapter will define medication-induced psychosis, differentiate this disorder from delirium, and discuss the drug classes most often associated with psychosis. Unlike many forms of psychosis, medication-induced psychosis does not have specific long-term psychiatric symptoms, prodromes, positive versus negative symptoms, common brain neuropathology, or genetic factors. It is neither gender specific nor age specific. The sole risk of medication-induced psychosis lies in a patient's general risk of developing a medical problem that requires the use of drug therapy.

Many medications when taken at therapeutic doses are associated with the development of psychotic symptoms (Anonymous, 2002). There are few large studies to substantiate these relationships; instead we must rely on case studies. Because many of these same medicines can also cause delirium (Trzepacz & Meagher, 2005), it is necessary to differentiate “delirium” from “psychosis” as there is obvious overlap between the disorders. Differentiating between drug-induced psychosis and delirium can be difficult. This distinction appears to be at least historically ambiguous if not controversial. Some texts group delirium in with “secondary psychoses” whose characteristic features of “clouding of consciousness” and “fluctuating course” differentiate them from primary psychoses. Charlton and Kavanau argue that most psychiatric conditions, including primary mental illness as well as intoxications have a delirious component to the disease (Charlton & Kavanau, 2002).

Type
Chapter
Information
The Spectrum of Psychotic Disorders
Neurobiology, Etiology and Pathogenesis
, pp. 406 - 452
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aderhold, R. M. & Muniz, C. E. (1970). Acute psychosis with amitriptyline and furazolidone. Journal of the American Medical Association, 213, 2080.Google Scholar
Ahmad, S. (1996). Losartan and reversible psychosis. Cardiology, 87, 569–70.Google Scholar
American Psychiatric Association (2000). Diagnosis and Statistical Manual of Mental Disorders. 4th edn, Text Revision. Washington, DC: American Psychiatric Association.
Anonymous (2002). Drugs that may cause psychiatric symptoms. Medical Letter on Drugs & Therapeutics, ed. Abramowicz, M., 44(1134), 59–62.
Apter, A., Ratzoni, G., King, R. A., et al. (1994). Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 342–8.Google Scholar
Baldessarini, R. J. & Willmuth, R. L. (1968). Psychotic reactions during amitriptyline therapy. Canadian Psychiatric Association Journal, 13, 571–3.Google Scholar
Barak, Y., Wohl, Y., Greenberg, Y., et al. (2005). Affective psychosis following accutane (isotretinoin) treatment. International Clinical Psychopharmacology, 20, 39–41.Google Scholar
Beeber, A. R. & Manring, J. M. Jr. (1983). Psychosis following cyclobenzaprine use. Journal of Clinical Psychiatry, 44, 151–2.Google Scholar
Bent, M. J., Bos, G. M., Sillevis Smitt, P. A., & Cornelissen, J. J. (1999). Erythropoietin induced visual hallucinations after bone marrow transplantation. Journal of Neurology, 246, 614–16.Google Scholar
Berger, M., White, J., Travis, L. B., et al. (1977). Toxic psychosis due to cyproheptadine in a child on hemodialysis: A case report. Clinical Nephrology, 7, 43–4.Google Scholar
Bessa, O. (1994). Acute psychosis due to indomethacin. Connecticut Medicine, 58(7), 395–6.Google Scholar
Bhatia, S. C., Arora, M., & Bhatia, S. K. (2001). Perceptual disturbances with zaleplon. Psychiatric Services, 52, 109–10.Google Scholar
Biswas, P. N., Wilton, L. V., & Shakir, S. A. (2003). The pharmacovigilance of mirtazapine: Results of a prescription event monitoring study on 13554 patients in England. Journal of Psychopharmacology, 17, 121–6.Google Scholar
Boyson, S. J. (1991). Psychiatric effects of selegiline, Archives of Neurology, 48, 902.Google Scholar
Breitbart, W., Marotta, R. F., & Call, P. (1988). AIDS and neuroleptic malignant syndrome. Lancet, 2(8626–7), 1488–9.Google Scholar
Brown, E. S. & Suppes, T. (1998). Mood symptoms during corticosteroid therapy: A review. Harvard Review Psychiatry, 5, 239–46.Google Scholar
Cancelli, I., Marcon, G., & Balestrieri, M. (2004). Factors associated with complex visual hallucinations during antidepressant treatment. Human Psychopharmacology, 19(8), 577–84.Google Scholar
Cantu, T. G. & Korek, J. S. (1991) Central nervous system reactions to histamine-2 receptor blockers. Annals of Internal Medicine, 114(12), 1027–34.Google Scholar
Capuron, L., Ravaud, A., & Dantzer, R. (2001). Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosomatic Medicine, 63(3), 376–86.Google Scholar
Capuron, L., Gumnick, J. F., Musselman, D. L., et al. (2002). Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology, 26, 643–52.Google Scholar
Catalano, G., Catalano, M. C., & Alberts, V. A. (1996). Famotidine-associated delirium. Psychosomatics, 37, 349–55.Google Scholar
Charlton, B. J. & Kavanau, J. L. (2002). Delirium and psychotic symptoms – an integrative model. Medical Hypotheses, 58, 24–7.Google Scholar
Chin, D. K. F., Cho, A. K., & Tse, C. Y. (1986). Neuropsychiatric complications related to use of prazosin in patients with renal failure. British Medical Journal, 293, 1347.Google Scholar
Chodorowski, Z., Sein Anand, J., & Wisniewski, M. (2004). Acute intoxication with baclofen. Przeglad Lekarski, 61(4), 389–91.Google Scholar
Christensen, R. C. (1995). Paroxetine-induced psychotic mania. American Journal of Psychiatry, 152, 1399–400.Google Scholar
Citrome, L., Levine, J., & Allingham, B. (2000). Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services, 51, 634–8.Google Scholar
Coleman, D. E. & Ota, K. (2004). Hallucinations with zolpidem and fluoxetine in an impaired driver. Journal of Forensic Sciences, 49, 392–3.Google Scholar
Cummings, J. L. & Back, C. (1998). The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. 6, 64–78.
Cummings, J. L. & Kaufer, D. I. (1996). Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology, 47, 876–83.Google Scholar
Daniel, D. G., Swallows, A., & Wolff, F. (1987). Capgras delusion and seizures in association with therapeutic dosages of disulfram. Southern Medical Journal, 80, 1577–80.Google Scholar
Defromont, L., Portenart, C., & Couvez, A. (1999). Psychiatric side effects of non-steroidal anti-inflammatory agents. French Encephale, 25, 11–15.Google Scholar
Denicoff, K. D., Rubinow, D. R., Papa, M. Z., et al. (1987) The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-actived killer cells. Annals of Internal Medicine, 107, 293–300.Google Scholar
Devulder, J., Laat, M., Dumoulin, K., Renson, A., & Rolly, G. (1996). Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. Acta Clinica Belgica, 51, 184–6.Google Scholar
Douglass, M. A. & Levine, D. P. (2000). Hallucinations in an elderly patient taking recommended doses of cyclobenzaprine. Archives of Internal Medicine, 160, 1373.Google Scholar
Duggal, H. S. & Singh, I. (2004). Worsening of psychosis or topiramate-induced adverse event. General Hospital Psychiatry, 26, 245–7.Google Scholar
Dunn, A. J., Wang, J., & Ando, T. (1999). Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Advances in Experimental Medicine & Biology, 461, 117–27.Google Scholar
Elko, C. J., Burgess, J. L., & Robertson, W. O. (1998). Zolpidem-associated hallucinations and serotonin reuptake inhibition: A possible interaction. Journal of Toxicology - Clinical Toxicology, 36, 195–203.Google Scholar
Evans, M., Perera, P. W., & Donoghue, J. (1997). Drug points: Drug induced psychosis with doxazosin. British Medical Journal, 314, 1869.Google Scholar
Fernandez, H. H., Trieschmann, M. E., Burke, M. A., Jaques, C., & Friedman, J. H. (2003). Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Movements Disorders, 18, 510–14.Google Scholar
Ferrie, C. D., Robinson, R. O., & Panayiotopoulos, C. P. (1996). Psychotic and severe behavioural reactions with vigabatrin: A review. Acta Neurologica Scandinavica, 93, 1–8.Google Scholar
Flores, B. H., Musselman, D. L., DeBattista, C., et al. (2004). Biology of mood disorders. In Textbook of Psychopharmacology, ed. Nemeroff, C. B., 3rd edn. Washington, DC: American Psychiatric Publishing, pp. 717–63.
Foster, R., Olajide, D., & Everall, I. P. (2003). Antiretroviral therapy-induced psychosis: Case report and brief review of the literature. HIV Medicine, 4, 139–44.Google Scholar
Friedman, J. H. (1991). The Management of the levodopa psychoses. Clinical Neuropharmacology, 14(4), 283–95.Google Scholar
Fuller, S. J., Naraqi, S., & Gilessi, G. (2002). Paranoid psychosis related to mefloquine antimalaria; prophylaxis. Papua New Guinea Medical Journal, 45, 219–21.Google Scholar
Garcia-Pares, G., Domenech, C., & Gil, M. (2002). Psychosis induced by interferon alpha, Psychosomatics, 43(5), 428.Google Scholar
Gatzonis, S. D., Angelopoulos, E.Sarigiannis, P., et al. (2003). Acute psychosis due to treatment with phenytoin in a nonepileptic patient. Epilepsy & Behavior, 4, 771–2.Google Scholar
Giupponi, G. & Erfurth, A. (1998). Transient psychosis in lisinopril-induced hyponatremia. Psychiatrische Praxis, 25, 204.Google Scholar
Golden, R. N., James, S. P., Sherer, M. A., et al. (1985). Psychoses associated with bupropion treatment. American Journal of Psychiatry, 142, 1459–62.Google Scholar
Goodman, A. B. (1998). Three independent lines of evidence to suggest retinoids as causal to schizophrenia. Proceedings of the National Academy of Science, 95, 7240–4.Google Scholar
Gopel, C., Laufer, C., & Marcus, A. (2002). Three cases of angel's trumpet tea-induced psychosis in adolescent substance abusers. Nordic Journal of Psychiatry, 56, 49–52.Google Scholar
Gordon, A. G. (1994). Musical hallucinations. Neurology, 44, 986–7.Google Scholar
Hall, R. C., Popkin, M. K., & Kirkpatrick, B. (1978). Tricyclic exacerbation of steroid psychosis. Journal of Nervous & Mental Disease, 166, 738–42.Google Scholar
Halpert, A. G., Olmstead, M. C., & Beninger, R. J. (2002). Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neuroscience & Biobehavioral Reviews, 26, 61–7.Google Scholar
Harsch, H. H. (1984). Mania in two patients following cyclobenzaprine. Psychosomatics, 25, 791–3.Google Scholar
Havaldar, P. V. & Mogale, K. D. (2000). Mefloquine-induced psychosis. Pediatric Infectious Disease Journal, 19(2), 166–7.Google Scholar
Hawkey, C. J. (1999). COX-2 inhibitors. Lancet, 353, 307–14.Google Scholar
Hemmingsen, R. & Rafaelsen, O. J. (1980). Hypnagogic and hypnopompic hallucinations during amitriptyline treatment. Acta Psychiatrica Scandinavica, 62, 364–8.Google Scholar
Hernandez, R., Juan, O., & Alberola, V. (2004). Ifosfamide-induced pyschosis. Acta Oncologica, 43, 119–20.Google Scholar
Hersh, C. B., Sokol, M. S., & Pfeffer, C. R. (1991). Transient psychosis with fluoxetine. Journal of the Academy of Child & Adolescent Psychiatry, 30, 851–2.Google Scholar
Hoffman, R. G., Cohen, M. A., Alfonso, C. A., et al. (2003) Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics, 44(5), 417–20.Google Scholar
Howard, W. T. & Warnock, J. K. (1999). Bupropion-induced psychosis. American Journal of Psychiatry, 156, 2017–18.Google Scholar
Hudgens, R. W., Tanna, V. L., Harley, J. D., & Leary, D. J. Jr. (1966). Visual hallucinations with iminodibenzyl antidepressants. Journal of the American Medical Association, 198, 199–200.Google Scholar
Iqbal, N. & Praag, H. M. (1995). The role of serotonin in schizophrenia. European Neuropsychopharmacology, 5(Suppl.), 11–13.Google Scholar
Iraqi, A. H. (2003). A case report of paranoid delusion with venlafaxine use. Journal of the American Geriatrics Society, 51, 1045–6.Google Scholar
Jablonowski, K., Margolese, H. C., & Chouinard, G. (2002). Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Canadian Journal of Psychiatry, 47(10), 975–6.Google Scholar
Jan Wise, M. E., Mistry, K., & Reid, S. (2002). Drug points: Neuropsychiatric complications of nevirapine treatment. British Medical Journal, 324, 879.Google Scholar
Jiang, H. K. & Chang, D. M. (1999). Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: Five case reports. Clinical Rheumatology, 18, 339–45.Google Scholar
Jick, S. S., Kremers, H. M., & Vasilakis-Scaramozza, C. (2000). Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Archives of Dermatology, 136, 1231–6.Google Scholar
Jones, I. H., Stevenson, J., Jordan, A., et al. (1973). Pheniramine as a hallucinogen. Medical Journal of Australia, 1, 382–6.Google Scholar
Keller, S. & Frishman, W. H. (2003). Neuropsychiatric effects of cardiovascular drug therapy. Cardiology in Review, 11, 73–93.Google Scholar
Kendler, K. S., Gallagher, T. J., Abelson, J. M., & Kessler, R. C. (1996). Lifetime prevalence, demographic risk factors, and diagnostic vulnerability of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Archives of General Psychiatry, 53, 1022–31.Google Scholar
Khouzam, H. R., Donnelly, N. J., & Ibrahim, N. F. (1998). Psychiatric morbidity in HIV patients. Canadian Journal of Psychiatry, 43, 51–6.Google Scholar
Kieburtz, K. D., Epstein, L. G., Gelbard, H. A., & Greenamyre, J. T. (1991). Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Archives of Neurology, 48, 1281–4.Google Scholar
Kim, D. (2000). A case of suspected alphagan-induced psychosis. Archives of Ophthalmology, 118, 1132–3.Google Scholar
Klein-Schwartz, W. (2002). Abuse and toxicity of methylphenidate. Current Opinion in Pediatrics, 2, 219–23.Google Scholar
Kukoyi, O. & Carney, C. P. (2003). Curses, madness, and mefloquine. Psychosomatics, 44(4), 339–41.Google Scholar
Kumagai, R., Ohnuma, T., Nagata, T., & Arai, H. (2003). Visual and auditory hallucinations with excessive intake of paroxetine. Psychiatry & Clinical Neurosciences, 57, 548–9.Google Scholar
Kurlan, R. & Dimitsopulos, T. (1992). Selegiline and manic behavior in Parkinson's disease, Archives of Neurology, 49, 1231.Google Scholar
Kuzuhara, S. (2001). Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. Journal of Neurology, 248(Suppl. 3), III/28–31.Google Scholar
Lamps, C. A. (2002). Citalopram and psychotic symptoms. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 6.Google Scholar
Lantz, M. S. & Giambanco, V. R. (2000). Acute onset of auditory hallucinations after initiation of celecoxib therapy. American Journal of Psychiatry, 157, 1022–3.Google Scholar
Lipowski, Z. J. (1990). Delirium: Acute Confusional States. New York: Oxford University Press.
Lissoni, P., Messina, G., Vaghi, M., et al. (2003). A psychoneuroendocrine study of brain dopaminergic sensitivity in locally limited or metastatic cancer patients. In Vivo, 17(6), 647–50.Google Scholar
Lu, M. L., Pan, J. J., Teng, H. W., Su, K. P., & Shen, W. W. (2002). Metoclopramide-induced supersensitivity psychosis. Annals of Pharmacotherapy, 36, 1387–90.Google Scholar
Major, L. F., Lerner, P., Ballenger, J. C., et al. (1979). Dopamine-beta-hydroxylase in the cerebrospinal fluid: Relationship to disulfram-induced psychosis. Biological Psychiatry, 14, 337–44.Google Scholar
Marcon, G., Cancelli, I., Zamarian, L., Bergonzi, P., & Balestrieri, M. (2004). Visual hallucinations with sertraline. Journal of Clinical Psychiatry, 65, 446–7.Google Scholar
Markowitz, J. S. & Brewerton, T. D. (1996). Zolpidem-induced psychosis. Annals of Clinical Psychiatry, 8, 89–91.Google Scholar
Markowitz, J. S., Rames, L. J., Reeves, N., & Thomas, S. G. (1997). Zolpidem and hallucinations. Annals of Emergency Medicine, 29, 300–1.Google Scholar
Merimsky, O., Reider-Groswasser, I., Wigler, N., & Chaitchik, S. (1992). Encephalopathy in ifosfamide-treated patients. Acta Neurologica Scandinavica, 86, 521–4.Google Scholar
Messina, G., Lissoni, P., Bartolacelli, E., et al. (2003). A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients. Journal of Biological Regulators & Homeostatic Agents, 17(4), 322–6.Google Scholar
Milgrom, H. & Bender, B. (1997). Adverse effects of medications for rhinitis. Annals of Allergy, Asthma, & Immunology, 78, 439–44.Google Scholar
Mirin, S. M., Schatzberg, A. F., & Creasey, D. E. (1981). Hypomania and mania after withdrawal of tricyclic antidepressants. American Journal of Psychiatry, 138, 87–9.Google Scholar
Mula, M., Trimble, M. R., Yuen, A., Liu, R. S. N., & Sander, J. W. A. S. (2003). Psychiatric adverse events during levetiracetam therapy. Neurology, 61, 704–6.Google Scholar
Muley, M. P., Joshi, M. A., & Manekar, M. S. (1984). Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice. Journal of Pharmacy & Pharmacology, 36, 208–10.Google Scholar
Murthy, K. K. (1997). Psychosis during disulfram therapy for alcoholism. Journal of the Indian Medical Association, 95, 80–1.Google Scholar
Narayan, M., Meckler, L., & Nelson, J. C. (1995). Fluoxetine-induced delusions in psychotic depression. Journal of Clinical Psychiatry, 56, 329.Google Scholar
Nelson, J. C., Bowers, M. B. Jr., & Sweeney, D. R. (1979). Exacerbation of psychosis by tricyclic antidepressants in delusional depression. American Journal of Psychiatry, 136, 574–6.Google Scholar
Nielsen, B., Nielsen, A., Sogaard, M., & Wraae, O. (2000). Factors associated with compliance of alcoholics in outpatient treatment. Journal of Nervous and Mental Disease, 188(2), 101–7.Google Scholar
Norra, C., Skobel, E., Brerer, C., et al. (2003). Ciprofloxacin-induced acute psychosis in a patient with multidrug-resistant tuberculosis. European Psychiatry, 18, 262–3.Google Scholar
O'Connel, G. J., Campbell, P. B., & Anath, J. V. (1972). Amitriptyline: Initial intolerance and subsequent psychosis. Canadian Medical Association Journal, 106, 115.Google Scholar
O'Donnell, J. (2003). Overview of existing research and information linking isotretinoin (accutane), depression, psychosis, and suicide. American Journal of Therapeutics, 10(2), 148–59.Google Scholar
Pallone, K. A., Goldman, M. P., & Fuller, M. A. (1993). Isoniazid-associated psychosis: Case report and review of the literature. The Annals of Phamacotherapy, 27, 167–70.Google Scholar
Patterson, J. F. (1984). Psychosis after discontinuation of nortriptyline. Journal of Clinical Psychopharmacology, 4, 117–18.Google Scholar
Pfeffer, F. & Grube, M. (2001). An organic psychosis due to a venlafaxine-propafenone interaction. International Journal of Psychiatry in Medicine, 31, 427–32.Google Scholar
Popli, A. P., Fuller, M. A., & Jaskiw, G. E. (1997). Sertraline and psychotic symptoms: A case series. Annals of Clinical Psychiatry, 9, 15–17.Google Scholar
Poulsen, H. D. & Lublin, H. K. F. (2003). Efavirenz-induced psychosis leading to involuntary detention. AIDS, 17(3), 451–3.Google Scholar
Prakash, R., Campbell, T. W., & Petrie, W. M. (1983). Psychoses with propranolol: A case report. Canadian Journal of Psychiatry, 28, 658–9.Google Scholar
Preda, A., MacLean, R. W., Mazure, C. M., & Bowers, M. B. Jr. (2001). Antidepressant-associated mania and psychosis resulting in psychiatric admissions. Journal of Clinical Psychiatry, 62, 30–3.Google Scholar
Quail, M. & Karelse, R. H. (1980). Disulfram psychosis. South African Medical Journal, 57, 551–2.Google Scholar
Rabinowitz, I. & Reis, S. (2001). Doctor, there's a fly in my soup! Angiotensin-converting enzyme inhibitors, endogenous opioids and visual hallucination. Israeli Medical Association Journal, 3, 963–4.Google Scholar
Rozzini, R., Inzoli, M., & Trabucchi, M. (1988). Delirium from transdermal scopolamine in an elderly woman. Journal of the American Medical Association, 260(4), 478.Google Scholar
Rundell, J. R. & Murray, G. B. (1988). Visual hallucinations on low dose amitriptyline. Journal of Clinical Psychopharmacology, 8, 75–6.Google Scholar
Schuld, A., Archelos, J. J., & Friess, E. (2000). Visual hallucinations and psychotic symptoms during treatment with selective serotonin reuptake inhibitors: Is the sigma receptor involved?Journal of Clinical Psychopharmacology, 20, 579–80.Google Scholar
Sewell, D. D., Jeste, D. V., Atkinson, J. H., et al. (1994). HIV-associated psychosis: A study of 20 cases. San Diego HIV Neurobehavioral Research Center Group. American Journal of Psychiatry, 151, 237–42.Google Scholar
Shepherd, G., Velez, L. I., & Keyes, D. C. (2004). Intentional bupropion overdoses. Journal of Emergency Medicine, 27, 147–51.Google Scholar
Shiovitz, T. M., Welke, T. L., Tigel, P. D., et al. (1996). Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophrenia Bulletin, 22(4), 591–5.Google Scholar
Sim, F. H. & Massabki, R. A. (2000). A single dose of fluvoxamine associated with an acute psychotic reaction. Canadian Journal of Psychiatry, 45, 762.Google Scholar
Sirois, F. (2003). Steroid psychosis: A review. General Hospital Psychiatry, 25, 27–33.Google Scholar
Smith, M. J. & Khayat, D. (1992). Residual acute confusional and hallucinatory syndromes induced by interleukin-2/alpha-interferon treatment. Psycho-Oncology, 1, 115–18.Google Scholar
Sowunmi, A., Adio, R. A., Oduola, A. M., Ogundahunsi, O. A., & Salako, L. A. (1995). Acute psychosis after mefloquine. Report of six cases. Tropical and Geographical Medicine, 47(4), 179–80.Google Scholar
Speich, R. & Haller, A. (1994). Central anticholinergic syndrome with the antimalarial drug mefloquine. New England Journal of Medicine, 331, 57–8.Google Scholar
Spigset, O. (1999). Adverse reactions of selective serotonin reuptake inhibitors: Reports from a spontaneous reporting system. Drug Safety, 20, 277–87.Google Scholar
Steinhert, J. & Pugh, C. R. (1979). Two patients with schizophrenic-like psychosis after treatment with beta-adrenergic blockers. British Medical Journal, 1(6166), 790.Google Scholar
Sternbach, H. & State, R. (1997). Antibiotics: Neuropsychiatric effects and psychotropic interactions. Harvard Review of Psychiatry, 5, 214–26.Google Scholar
Stevinson, C. & Ernst, E. (2004). Can St. John's wort trigger psychoses?International Journal of Clinical Pharmacology & Therapeutics, 42, 473–80.Google Scholar
Tamam, L., Yerdelen, D., & Ozpoyraz, N. (2003). Psychosis associated with interferon alfa therapy for chronic hepatitis B, Annals of Pharmacotherapy, 37, 384–7.Google Scholar
Tarlow, M. M., Sakaris, A., Scoyoni, R., & Wolf-Klein, G. (2000). Quinopril-associated acute psychosis in an older woman. Journal of the American Geriatrics Society, 48, 1533.Google Scholar
Terao, T. (1995). Tricyclic-induced musical hallucinations and states of relative sensory deprivation. Biological Psychiatry, 38, 192–3.Google Scholar
The Parkinson Study Group (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease: The parkinson study group. New England Journal of Medicine, 340, 757–63.
Timnak, C. & Gleason, O. (2004). Promethazine-induced psychosis in a 16-year-old girl. Psychosomatics, 45, 89–90.Google Scholar
Trimble, M. R. (1996). Anticonvulsant-induced psychiatric disorders. The role of forced normalization. Drug Safety, 15(3), 159–66.Google Scholar
Tripathi, A., Chen, S. I., & O'Sullivan, S. (2002). Acute psychosis following the use of topical ciprofloxacin. Archives of Ophthalmology, 120, 665–6.Google Scholar
Trepacz, P. T. (2000). Is there a common neural pathway in delirium? Focus on acetylcholine and dopamine. Seminars in Clinical Neuropsychiatry, 5(2), 132–48.Google Scholar
Trepacz, P. T. & Meagher, D. J. (2005). Delirium. In Textbook of Psychosomatic Medicine, ed. Levenson, J. L.. Washington, DC: American Psychiatric Publishing, pp. 91–130.
Ueda, N., Terao, T., Ohmori, O., & Nakamura, J. (2003). Schneiderian first-rank symptoms associated with fluvoxamine treatment: A case report. Human Psychopharmacology, 18, 477–8.Google Scholar
Uzych, L. (1992). Anabolic-androgenic steroids and psychiatric-related effects: A review. Canadian Journal of Psychiatry, 37, 23–8.Google Scholar
Muhlendahl, K. E. & Krienke, E. G. (1978). Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl.). GermanMonatsschrift fur Kinderheilkunde, 126, 123–6.Google Scholar
Walton, R. & Manos, G. H. (2003). Psychosis related to ephedra-containing herbal supplement use. Southern Medical Journal, 96, 718–20.Google Scholar
Wang, T. S., Shiah, I. S., Yeh, C. B., & Chang, C. C. (2005). Acute psychosis following sustained release bupropion overdose. Progress in Neuropsychopharmacology and Biological Psychiatry, 29(1), 149–51.Google Scholar
Watemberg, N. M., Roth, K. S., Alehan, F. K., & Epstein, C. E. (1999). Central anticholinergic syndrome on therapeutic doses of cyproheptadine. Pediatrics, 103, 158–60.Google Scholar
Webb, A. & Cranswick, N. (2003). Fluoxetine induced auditory hallucinations in an adolescent. Journal of Paediatrics & Child Health, 39, 637–8.Google Scholar
Wilkaitis, J., Mulvihill, T., & Nasrallah, H. (2004). Classic antipsychotic medications. In Textbook of Psychopharmacology, ed. Nemeroff, C. B., 3rd edn. Washington, DC: American Psychiatric Publishing, pp. 425–41.
Yassa, R. Y. & Iskandar, H. L. (1988). Baclofen-induced psychosis: Two cases and a review. Journal of Clinical Psychiatry, 49(8), 318–20.Google Scholar
Yi Chau, S. & Chiu Mok, C. (2003). Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology, 61(1), 104–7.Google Scholar
Young, B. K., Camicioli, R., & Ganzini, L. (1997). Neuropsychiatric adverse effects of antiparkinsonian drugs. Drugs and Aging, 10(5), 367–83.Google Scholar
Zifko, U. A., Rupp, M., Schwarz, S., Zipko, H. T., & Maida, E. M. (2002). Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. Journal of Neurology, 249(8), 983–7.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×